Sanofi India Limited has informed the Exchange regarding Outcome of Board Meeting held on May 14, 2025.
SANOFI · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 3.2 pts more than Nifty Microcap 250 and 3.9 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Sanofi India's Board approved its Q1 2025 unaudited financial results on May 14, 2025. Net sales from continuing operations grew about 5% year-on-year to Rs 5,359 million (from Rs 5,108 million), with the company highlighting a 4% comparable growth after adjusting for the Consumer Healthcare demerger effective June 1, 2024. Operating profit jumped 27% to Rs 1,653 million, driven by lower expenses and operating efficiencies. Profit from continuing operations rose sharply to Rs 1,195 million (EPS of Rs 51.89) versus Rs 720 million (EPS of Rs 31.26) in Q1 2024. The launch of Soliqua, a diabetes drug, continued to see steady growth.
Strong margin expansion and a 66% jump in profit from continuing operations should be viewed positively by shareholders, signaling improved operational efficiency post the Consumer Healthcare demerger. The result is likely to be supportive of the stock price in the near term.